152 related articles for article (PubMed ID: 19567506)
1. Eligibility for magnetic resonance imaging screening in the United Kingdom: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS Study.
Evans DG; Lennard F; Pointon LJ; Ramus SJ; Gayther SA; Sodha N; Kwan-Lim GE; Leach MO; Warren R; Thompson D; Easton DF; Eeles R;
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2123-31. PubMed ID: 19567506
[TBL] [Abstract][Full Text] [Related]
2. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).
Leach MO; Boggis CR; Dixon AK; Easton DF; Eeles RA; Evans DG; Gilbert FJ; Griebsch I; Hoff RJ; Kessar P; Lakhani SR; Moss SM; Nerurkar A; Padhani AR; Pointon LJ; Thompson D; Warren RM;
Lancet; 2005 May 21-27; 365(9473):1769-78. PubMed ID: 15910949
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer.
Griebsch I; Brown J; Boggis C; Dixon A; Dixon M; Easton D; Eeles R; Evans DG; Gilbert FJ; Hawnaur J; Kessar P; Lakhani SR; Moss SM; Nerurkar A; Padhani AR; Pointon LJ; Potterton J; Thompson D; Turnbull LW; Walker LG; Warren R; Leach MO;
Br J Cancer; 2006 Oct; 95(7):801-10. PubMed ID: 17016484
[TBL] [Abstract][Full Text] [Related]
4. Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features.
Gilbert FJ; Warren RM; Kwan-Lim G; Thompson DJ; Eeles RA; Evans DG; Leach MO;
Radiology; 2009 Aug; 252(2):358-68. PubMed ID: 19703879
[TBL] [Abstract][Full Text] [Related]
5. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results.
Sardanelli F; Podo F; D'Agnolo G; Verdecchia A; Santaquilani M; Musumeci R; Trecate G; Manoukian S; Morassut S; de Giacomi C; Federico M; Cortesi L; Corcione S; Cirillo S; Marra V; ; Cilotti A; Di Maggio C; Fausto A; Preda L; Zuiani C; Contegiacomo A; Orlacchio A; Calabrese M; Bonomo L; Di Cesare E; Tonutti M; Panizza P; Del Maschio A
Radiology; 2007 Mar; 242(3):698-715. PubMed ID: 17244718
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
[TBL] [Abstract][Full Text] [Related]
7. Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
Shimada S; Yoshida R; Nakashima E; Kitagawa D; Gomi N; Horii R; Takeuchi S; Ashihara Y; Kita M; Akiyama F; Ohno S; Saito M; Arai M
Breast Cancer; 2019 Nov; 26(6):846-851. PubMed ID: 30980249
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.
Plevritis SK; Kurian AW; Sigal BM; Daniel BL; Ikeda DM; Stockdale FE; Garber AM
JAMA; 2006 May; 295(20):2374-84. PubMed ID: 16720823
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group.
Anglian Breast Cancer Study Group
Br J Cancer; 2000 Nov; 83(10):1301-8. PubMed ID: 11044354
[TBL] [Abstract][Full Text] [Related]
10. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
Warner E; Plewes DB; Hill KA; Causer PA; Zubovits JT; Jong RA; Cutrara MR; DeBoer G; Yaffe MJ; Messner SJ; Meschino WS; Piron CA; Narod SA
JAMA; 2004 Sep; 292(11):1317-25. PubMed ID: 15367553
[TBL] [Abstract][Full Text] [Related]
11. Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies.
Evans DG; Harkness E; Lalloo F; Howell A
J Med Genet; 2014 Sep; 51(9):573-80. PubMed ID: 25053764
[TBL] [Abstract][Full Text] [Related]
12. The incidence of breast cancer from screening women according to predicted family history risk: Does annual clinical examination add to mammography?
Gui GP; Hogben RK; Walsh G; A'Hern R; Eeles R
Eur J Cancer; 2001 Sep; 37(13):1668-73. PubMed ID: 11527694
[TBL] [Abstract][Full Text] [Related]
13. Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined.
Heijnsdijk EA; Warner E; Gilbert FJ; Tilanus-Linthorst MM; Evans G; Causer PA; Eeles RA; Kaas R; Draisma G; Ramsay EA; Warren RM; Hill KA; Hoogerbrugge N; Wasser MN; Bergers E; Oosterwijk JC; Hooning MJ; Rutgers EJ; Klijn JG; Plewes DB; Leach MO; de Koning HJ
Cancer Epidemiol Biomarkers Prev; 2012 Sep; 21(9):1458-68. PubMed ID: 22744338
[TBL] [Abstract][Full Text] [Related]
14. Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence.
Shah P; Rosen M; Stopfer J; Siegfried J; Kaltman R; Mason B; Armstrong K; Nathanson KL; Schnall M; Domchek SM
Breast Cancer Res Treat; 2009 Dec; 118(3):539-46. PubMed ID: 19609668
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer and ovarian cancer genetics.
Edlich RF; Winters KL; Lin KY
J Long Term Eff Med Implants; 2005; 15(5):533-45. PubMed ID: 16218901
[TBL] [Abstract][Full Text] [Related]
16. The UK national study of magnetic resonance imaging as a method of screening for breast cancer (MARIBS).
Leach MO; Eeles RA; Turnbull LW; Dixon AK; Brown J; Hoff RJ; Coulthard A; Dixon JM; Easton DF; Evans DG; Gilbert FJ; Hawnaur J; Hayes C; Kessar P; Lakhani S; Liney G; Moss SM; Padhani AP; Pointon LJ; Sydenham M; Walker LG; Warren RM; Haites NE; Morrison P; Cole T; Rayter Z; Donaldson A; Shere M; Rankin J; Goudie D; Steel CM; Davidson R; Chu C; Ellis I; Mackay J; Hodgson SV; Homfray T; Douglas F; Quarrell OW; Eccles DM; Gilbert FG; Crothers G; Walker CP; Jones A; Slack N; Britton P; Sheppard DG; Walsh J; Whitehouse G; Teh W; Rankin S; Boggis C; Potterton J; McLean L; Gordon PA; Rubin C;
J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):107-14. PubMed ID: 12585664
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience.
Cortesi L; Turchetti D; Marchi I; Fracca A; Canossi B; Rachele B; Silvia R; Rita PA; Pietro T; Massimo F
BMC Cancer; 2006 Aug; 6():210. PubMed ID: 16916448
[TBL] [Abstract][Full Text] [Related]
18. Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography.
van Zelst JCM; Mus RDM; Woldringh G; Rutten MJCM; Bult P; Vreemann S; de Jong M; Karssemeijer N; Hoogerbrugge N; Mann RM
Radiology; 2017 Nov; 285(2):376-388. PubMed ID: 28609204
[TBL] [Abstract][Full Text] [Related]
19. Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness.
de Bock GH; Vermeulen KM; Jansen L; Oosterwijk JC; Siesling S; Dorrius MD; Feenstra T; Houssami N; Greuter MJ
Br J Cancer; 2013 Apr; 108(8):1579-86. PubMed ID: 23579217
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status.
Evans DG; Moran A; Hartley R; Dawson J; Bulman B; Knox F; Howell A; Lalloo F
Br J Cancer; 2010 Mar; 102(7):1091-8. PubMed ID: 20234365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
